JP2008508886A5 - - Google Patents

Download PDF

Info

Publication number
JP2008508886A5
JP2008508886A5 JP2007525034A JP2007525034A JP2008508886A5 JP 2008508886 A5 JP2008508886 A5 JP 2008508886A5 JP 2007525034 A JP2007525034 A JP 2007525034A JP 2007525034 A JP2007525034 A JP 2007525034A JP 2008508886 A5 JP2008508886 A5 JP 2008508886A5
Authority
JP
Japan
Prior art keywords
seq
reading frame
open reading
active bont
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007525034A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008508886A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/027917 external-priority patent/WO2006017749A2/en
Publication of JP2008508886A publication Critical patent/JP2008508886A/ja
Publication of JP2008508886A5 publication Critical patent/JP2008508886A5/ja
Pending legal-status Critical Current

Links

JP2007525034A 2004-08-04 2005-08-03 活性ボツリヌス毒素ａ型の発現の最適化 Pending JP2008508886A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59912104P 2004-08-04 2004-08-04
PCT/US2005/027917 WO2006017749A2 (en) 2004-08-04 2005-08-03 Optimizing expression of active botulinum toxin type a

Publications (2)

Publication Number Publication Date
JP2008508886A JP2008508886A (ja) 2008-03-27
JP2008508886A5 true JP2008508886A5 (https=) 2008-09-18

Family

ID=35355531

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007525034A Pending JP2008508886A (ja) 2004-08-04 2005-08-03 活性ボツリヌス毒素ａ型の発現の最適化

Country Status (6)

Country Link
US (2) US20080057575A1 (https=)
EP (1) EP1773874B1 (https=)
JP (1) JP2008508886A (https=)
AU (1) AU2005271372B2 (https=)
CA (1) CA2575994A1 (https=)
WO (1) WO2006017749A2 (https=)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514088B2 (en) 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
JP2008508886A (ja) * 2004-08-04 2008-03-27 アラーガン、インコーポレイテッド 活性ボツリヌス毒素ａ型の発現の最適化
JP4994241B2 (ja) 2004-11-22 2012-08-08 ニューヨーク・ユニバーシティ 遺伝子操作されたクロストリジウム遺伝子、操作された遺伝子によりコードされるタンパク質、およびその使用
ES2369558T3 (es) 2005-09-19 2011-12-01 Allergan, Inc. Toxinas clostridiales y toxinas clostridiales activables.
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
EP2021489A2 (en) * 2006-05-30 2009-02-11 Dow Global Technologies Inc. Codon optimization method
CA2693958A1 (en) 2007-06-14 2008-12-18 Emergent Biosolutions, Inc. Chemically modified peptides with improved immunogenicity
KR20110106346A (ko) 2008-12-10 2011-09-28 알러간, 인코포레이티드 클로스트리디움 독소 약제학적 조성물
EP2218783A1 (en) 2009-02-05 2010-08-18 Merz Pharma GmbH & Co. KGaA Novel method for the manufacturing of neurotoxins
ES2770033T3 (es) 2009-03-13 2020-06-30 Allergan Inc Ensayos de actividad de endopeptidasa redirigida basados en inmunología
KR20120107988A (ko) 2009-12-16 2012-10-04 알러간, 인코포레이티드 통합된 프로테아제 절단 부위 결합 도메인을 포함하는 변형 클로스트리듐 독소
SI2684890T1 (sl) 2010-01-25 2016-10-28 Allergan, Inc. Metode znotrajcelične pretvorbe enoverižnih beljakovin v njihovo dvoverižno obliko
WO2011091419A2 (en) * 2010-01-25 2011-07-28 New York Universiy Recombinant derivatives of botulinum neurotoxins engineered for trafficking studies and neuronal delivery
RU2560577C2 (ru) 2010-11-23 2015-08-20 Аллерган, Инк. Композиции и способы получения энтерокиназы в дрожжах
US20120244188A1 (en) 2011-03-25 2012-09-27 Allergan, Inc. Treatment of Sensory Disturbance Disorders
US20120251574A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions
US20120251573A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Neuroendocrine Disorders
US20120251575A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Involuntary Movement Disorders
US20120251519A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Smooth Muscle Disorders
US20120258132A1 (en) 2011-03-29 2012-10-11 Allergan, Inc. Vagal Nerve-Based Disorders
US20120251518A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Sexual Dysfunction Disorders
US20120251515A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Cosmesis Disorders
US8849411B2 (en) * 2011-05-17 2014-09-30 Boston Scientific Neuromodulation Corporation User-defined graphical shapes used as a visualization aid for stimulator programming
WO2012174123A1 (en) 2011-06-13 2012-12-20 Allergan, Inc. Treatment of psychological trauma
WO2013091895A1 (en) 2011-12-23 2013-06-27 Merz Pharma Gmbh & Co. Kgaa Novel method for the manufacturing of di-chain proteins for use in humans
US20130171122A1 (en) 2011-12-29 2013-07-04 Allergan, Inc. Endopeptidase and neurotoxin combination treatment of bladder disorders
WO2014079495A1 (en) 2012-11-21 2014-05-30 Syntaxin Limited Methods for the manufacture of proteolytically processed polypeptides
WO2014117148A1 (en) 2013-01-28 2014-07-31 New York University Treatment methods using atoxic neurotoxin derivatives
KR20150127585A (ko) * 2013-03-15 2015-11-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 보툴리누스균의 혈청형으로부터의 중쇄를 사용한 1가 또는 다가 보툴리늄 신경독소 기반 백신
ES2704237T3 (es) 2014-03-05 2019-03-15 Merz Pharma Gmbh & Co Kgaa Nuevas neurotoxinas clostridiales recombinantes con un aumento de la duración del efecto
EP3230457B1 (en) 2014-12-09 2021-06-30 New York University Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use
AU2015367329B2 (en) 2014-12-19 2021-02-18 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the biological activity of BoNT/E in cells
CN107108703B (zh) 2015-01-09 2022-09-23 益普生生物创新有限公司 阳离子神经毒素
TW201718627A (zh) 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
US11078472B2 (en) 2016-01-20 2021-08-03 Merz Pharma Gmbh & Co., Kgaa Recombinant clostridial neurotoxins with increased duration of effect
MX395130B (es) 2016-03-02 2025-03-24 Merz Pharma Gmbh & Co Kgaa Composicion que comprende toxina botulinica
EP3290437A1 (en) 2016-08-31 2018-03-07 Merz Pharma GmbH & Co. KGaA Novel recombinant clostridial neurotoxins with decreased duration of effect
BR112019004935A2 (pt) 2016-09-13 2019-06-04 Allergan, Inc. composições de toxina clostridial não proteíca estabilizada
EP3312193A1 (en) 2016-10-19 2018-04-25 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with accelerated onset of effect
EP3333179A1 (en) 2016-12-07 2018-06-13 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum toxin with accelarated onset of effect
EP3335719A1 (en) 2016-12-14 2018-06-20 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with a stabilized light chain
WO2018233813A1 (en) 2017-06-20 2018-12-27 Merz Pharma Gmbh & Co. Kgaa Novel recombinant botulinum toxin with increased duration of effect
ES2930237T3 (es) 2017-07-06 2022-12-09 Merz Pharma Gmbh & Co Kgaa Neurotoxinas botulínicas recombinantes nuevas con mayor duración de efectos
US20210008156A1 (en) 2017-10-26 2021-01-14 Merz Pharma Gmbh & Co. Kgaa Novel recombinant botulinum neurotoxins with increased duration of effect
WO2019101308A1 (en) 2017-11-22 2019-05-31 Merz Pharma Gmbh & Co. Kgaa Novel recombinant botulinum toxin with increased duration of effect
WO2019152380A1 (en) * 2018-01-30 2019-08-08 Children's Medical Center Corporation Production of botulinum neurotoxins using bacillus systems
EP3752128B1 (de) * 2018-02-16 2025-01-15 preclinics discovery GmbH Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung
WO2020174079A1 (en) * 2019-02-28 2020-09-03 Proteonic Biotechnology Ip B.V. Self-immolative plasmid backbone
WO2022197623A1 (en) * 2021-03-15 2022-09-22 Children's Medical Center Corporation Engineered botulinum neurotoxin a protease domain with improved efficacy
GB202104294D0 (en) * 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2003383A1 (en) * 1988-11-23 1990-05-23 Sushil G. Devare Synthetic dna derived recombinant hiv antigens
UA48104C2 (uk) * 1991-10-04 2002-08-15 Новартіс Аг Фрагмент днк, який містить послідовність,що кодує інсектицидний протеїн, оптимізовану для кукурудзи,фрагмент днк, який забезпечує направлену бажану для серцевини стебла експресію зв'язаного з нею структурного гена в рослині, фрагмент днк, який забезпечує специфічну для пилку експресію зв`язаного з нею структурного гена в рослині, рекомбінантна молекула днк, спосіб одержання оптимізованої для кукурудзи кодуючої послідовності інсектицидного протеїну, спосіб захисту рослин кукурудзи щонайменше від однієї комахи-шкідника
US7214787B1 (en) * 1993-09-21 2007-05-08 United States Of America As Represented By The Secretary Of The Army Recombinant vaccine against botulinum neurotoxin
US7037680B2 (en) * 1993-09-21 2006-05-02 The United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
CA2203504A1 (en) * 1994-10-24 1996-05-02 James A. Williams Vaccine and antitoxin for treatment and prevention of c. difficile disease
US6114148C1 (en) * 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
EP1020517A4 (en) * 1997-07-11 2004-11-17 Chugai Pharmaceutical Co Ltd Gene originating in human chondrocyte
US6277622B1 (en) * 1997-08-11 2001-08-21 The University Of Sydney Synthetic polynucleotides
US6218188B1 (en) * 1997-11-12 2001-04-17 Mycogen Corporation Plant-optimized genes encoding pesticidal toxins
US6214602B1 (en) * 1998-08-28 2001-04-10 Promega Corporation Host cells for expression of clostridial toxins and proteins
CA2371279A1 (en) * 1999-05-12 2000-11-16 Leonard A. Smith Recombinant vaccine against botulinum neurotoxin
US6399857B1 (en) * 1999-09-22 2002-06-04 Paradigm Genetics, Inc. Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species
AU1152402A (en) * 2000-10-04 2002-04-15 Univ Pennsylvania Highly expressible genes
DE60336736D1 (de) * 2002-07-16 2011-05-26 VGX Pharmaceuticals LLC Codon-optimierte synthetische plasmide
JP2008508886A (ja) * 2004-08-04 2008-03-27 アラーガン、インコーポレイテッド 活性ボツリヌス毒素ａ型の発現の最適化

Similar Documents

Publication Publication Date Title
JP2008508886A5 (https=)
Shi et al. The low molecular mass subunits of the photosynthetic supracomplex, photosystem II
Pfeifer Distribution, formation and regulation of gas vesicles
JP2009148257A5 (https=)
Von Caemmerer C4 photosynthesis in a single C3 cell is theoretically inefficient but may ameliorate internal CO2 diffusion limitations of C3 leaves
CO5680484A2 (es) Moleculas de ligando gitr y relacionadas con ligando gitr y anticuerpos y usos de estas
JP2010279377A5 (https=)
EA200900512A1 (ru) Метаболическая инженерия сбраживающих арабинозу дрожжевых клеток
WO2005069762A8 (en) Bacillus licheniformis chromosome
ATE512980T1 (de) Polypeptide mit beta-glucosidase-aktivität sowie diese codierende polynukleotide
JP2011516063A5 (https=)
JP2009502127A5 (https=)
JP2017532039A5 (https=)
HUE031212T2 (en) Preparation of isobutanol by fermentation with yeast
JP2006526394A5 (https=)
JP2007175057A5 (https=)
EP4449858A3 (en) Compositions and methods for enhancing resistance to northern leaf blight in maize
JP2010501167A5 (https=)
JP2010530223A5 (https=)
Tiwari et al. A critical review on the advancement of the development of low-cost membranes to be utilized in microbial fuel cells
WO2007020198A3 (en) Nucleic acid sequences encoding proteins associated with abiotic stress response and plant cells and plants with increased tolerance to environmental stress
WO2008041863A8 (en) Novel genes and polypeptides associated with insecticidal activity
JP2005532815A5 (https=)
WO2009058030A3 (en) Resistance gene and uses thereof
JP2011527367A5 (https=)